Ashish Tripathi, founder and CEO of Tzar Labs, as well as chairman of Epigeneres Biotech, the Indian firm where the test was first developed in 2021, has published a study this month in the journal Stem Cells, saying that they have found a breakthrough ‘holy grail’ of cancer detection that predicts tumors a year before they form.